Keywords: Ipsen, Taspoglutide, Roche, Diabetes, Financial results 2010

Blow for Ipsen as Roche drops taspoglutide, but good news on IB1001, as French drugmaker posts 5% rise in 2010 sales

Article | 03 February 2011

Print This

French drugmaker Ipsen (Euronext: IPN) suffered a significant setback yesterday, when Swiss major Roche (ROG: VX) informed the group of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in